Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société França
about
Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell TransplantationDonor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell TransplantationDesensitization for solid organ and hematopoietic stem cell transplantationDonor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation.Donor Selection for Allogenic Hemopoietic Stem Cell Transplantation: Clinical and Ethical Considerations.Umbilical cord blood transplantation: the first 25 years and beyond.The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children.Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease.Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation setsComplement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell TransplantationEngraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen.Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application.Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.Sustained donor engraftment in recipients of double-unit cord blood transplantation is possible despite donor-specific human leukoctye antigen antibodiesClinical utilization of cord blood over human health: experience of stem cell transplantation and cell therapy using cord blood in Korea.Improving engraftment and immune reconstitution in umbilical cord blood transplantation.Donor HLA-specific Abs: to BMT or not to BMT?Umbilical cord blood graft engineering: challenges and opportunities.Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols.Impact of HLA in cord blood transplantation outcomes.Leukoreduced red blood cell transfusions do not induce platelet glycoprotein antibodies in patients with sickle cell disease.BSHI Guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation.Class I and II HLA antibodies in pediatric patients with thalassemia major.Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality.The 'HLA conundrum in bone marrow transplantation': correct interpretation of anti-HLA antibodies in haploidentical donor selection.Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation.The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.Pretransplant platelet transfusion refractoriness is not associated with platelet nonengraftment in T-replete hematopoietic progenitor cell transplantation for hematologic malignancies.Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study.Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation.
P2860
Q26738469-CF2C7ADA-AABE-4F47-813D-2364C1B7E6FCQ26767440-B1BED302-13B2-40A0-B29E-7B18F4B751A9Q26863564-5AAE39E4-D569-4007-95E1-CA8AD898CD62Q33441698-58AB46AA-4720-4AD9-BE6F-CE9C0AF359D0Q33819995-936CF94D-3620-426D-9B95-0B15FDFA4A15Q34344669-287ED96E-D71E-4431-9839-264F14066F01Q34973409-72EC0CE2-9966-4698-B498-4D1B1013DB01Q35811966-4B79CDFA-82AA-4FD8-BA43-6AD35857D659Q35834570-57CEA85C-1638-45B2-A586-9BC5184A8513Q35864018-D003E9A5-3F39-4B82-9122-A51ECA5E99E6Q36036346-55976713-96A9-4AA5-A3B3-70392D5F7834Q36605814-1889A7C8-5182-4B21-8752-65581894BEB3Q36902123-2F5CC7D0-2B9B-4866-92C2-E166C0296185Q37602004-5A7884EE-626A-4F7A-BAAC-B2E692502CA5Q37699562-7CEAC4CE-B615-42D6-A523-D368BCF0C717Q37725142-2F26D9DF-0A8E-4835-AA13-9DD1FE1763DAQ38194133-E6EEC491-15BE-41F6-A984-7207E926A72EQ38364329-FA6BB11E-BB5D-41FA-894B-A1B67E32F9AEQ38514503-62AC40AB-E2ED-42C9-B49C-4324A280710AQ38636111-C3D9C2E9-098D-44EE-83DB-915B128C3EDCQ38802750-8C83B556-FEF5-43D2-BB84-CB4BBF79FB84Q38844594-C683CF0B-90F4-46AF-B6C4-2E38C035FAA2Q38922475-48040B41-7314-4E2E-89CF-7A6A34083F10Q38932133-ED91DE38-E0BB-42E4-B52C-9FB0285AEE22Q40883726-E094A9CB-796B-4759-92ED-8DD5233E6F1AQ46123564-38BAD05A-80A3-416E-9012-FAFB18AEE8E7Q48217989-D39AFECA-6221-4418-82FA-236AA1740995Q48337197-605C1FB4-63AC-45A5-9F42-AE7A047AD6F8Q50042370-FA95FD56-2242-4D6D-8596-1D6A4F772B7DQ50438477-245B101A-4EA4-43D1-8A71-0C85EFD1C659Q52688938-AE75B19B-8D6C-40CE-81E2-3664B73BEA0AQ52794502-B38EE2BE-B514-48D2-86F2-E5DD6591010D
P2860
Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société França
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Impact of donor-specific anti- ...... ique (SFHI) and Société França
@en
type
label
Impact of donor-specific anti- ...... ique (SFHI) and Société França
@en
prefLabel
Impact of donor-specific anti- ...... ique (SFHI) and Société França
@en
P2093
P2860
P1433
P1476
Impact of donor-specific anti- ...... ique (SFHI) and Société França
@en
P2093
Ali Boudifa
Annalisa Ruggeri
Anne Devys
Annie Ramouneau-Pigot
Beatrice Pedron
Brigitte Coeffic
Christophe Picard
Daniel Hanau
Dominique Charron
Dominique Masson
P2860
P304
P356
10.3324/HAEMATOL.2012.077685
P577
2012-12-14T00:00:00Z